Showing 1 - 10 of 10
Persistent link: https://www.econbiz.de/10001445331
Study of trade-related aspects of intellectual property rights (TRIPS) has formed an integral part of the work program of the Committee on International Trade Law of the International Law Association (ILA) since its inaugural meeting at the headquarters of the GATT in 1993. In June 1995 in...
Persistent link: https://www.econbiz.de/10014178000
This article addresses the relationship between the GATT, the European Community and other RTAs as and when trade in services and other 'new areas' are incorporated into the GATT framework. The article first discusses the conceptual justifications for RTAs (as an alternative to utopian global...
Persistent link: https://www.econbiz.de/10014178186
During the past several years, the United States has concluded a substantial number of bilateral and regional free trade agreements (hereinafter “FTAs”), largely with developing countries. Each of those FTAs includes substantial commitments in the field of intellectual property rights (IPRs)...
Persistent link: https://www.econbiz.de/10014178512
This paper addresses the specific question whether “development-friendly” provisions incorporated in recent European Union (EU) economic partnership agreements (EPAs) may serve as models for the progressive development of international intellectual property law. Other articles in this volume...
Persistent link: https://www.econbiz.de/10014159107
In connection with the run-up to the Cancun Ministerial Conference, the author was asked whether there are grounds for recommending amendment of WTO TRIPS Agreement rules addressing competition. The general conclusion of the study is that the TRIPS Agreement in its present form provides...
Persistent link: https://www.econbiz.de/10012754182
The COVID-19 pandemic has caused Governments to contemplate measures to override patents and other intellectual property rights (IPRs) in order to facilitate production and distribution of vaccines, treatments, diagnostics and medical devices. This paper discusses whether the COVID-19 pandemic...
Persistent link: https://www.econbiz.de/10012824544
Persistent link: https://www.econbiz.de/10012875418
Prosecution of pharmaceutical companies for excessive pricing of products under competition law is now a reality. As recently as a decade ago, such prosecutions were virtually nonexistent. That situation has changed dramatically as competition authorities in Europe and South Africa have pursued...
Persistent link: https://www.econbiz.de/10014263570